StockData
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.81+0.02 (+0.35%)

Close on Nov 16, 2026Market cap $297.90MP/E –Yield –

Emergent BioSolutions cash

Cash and short-term investments held at the end of each period.

Emergent BioSolutions's cash was $175.70M at Sep 30, 2026. For fiscal 2025 it was $205.40M, up 94.5% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $642.60M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$205.40M+94.5%
FY2024Dec 31, 2024$105.60M-5.5%
FY2023Dec 31, 2023$111.70M-82.6%
FY2022Dec 31, 2022$642.60M+11.5%
FY2021Dec 31, 2021$576.30M-7.3%
FY2020Dec 31, 2020$621.50M+269.9%
FY2019Dec 31, 2019$168.00M+49.5%
FY2018Dec 31, 2018$112.40M-37.3%
FY2017Dec 31, 2017$179.30M-34.2%
FY2016Dec 31, 2016$272.50M-12.9%
FY2015Dec 31, 2015$312.80M+11.5%
FY2014Dec 31, 2014$280.50M+56.4%
FY2013Dec 31, 2013$179.34M+26.6%
FY2012Dec 31, 2012$141.67M-2.9%
FY2011Dec 31, 2011$145.87M-14.7%
FY2010Dec 31, 2010$171.05M+66.2%
FY2009Dec 31, 2009$102.92M+12.5%
FY2008Dec 31, 2008$91.47M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$175.70M-28.4%
Q2 FY2026Jun 30, 2026$139.70M-47.7%
Q1 FY2026Mar 31, 2026$160.30M+7.5%
Q4 FY2025Dec 31, 2025$205.40M+94.5%
Q3 FY2025Sep 30, 2025$245.50M+63.8%
Q2 FY2025Jun 30, 2025$267.30M+283.5%
Q1 FY2025Mar 31, 2025$149.10M+89.9%
Q4 FY2024Dec 31, 2024$105.60M-5.5%
Q3 FY2024Sep 30, 2024$149.90M+70.7%
Q2 FY2024Jun 30, 2024$69.70M-21.3%
Q1 FY2024Mar 31, 2024$78.50M-81.8%
Q4 FY2023Dec 31, 2023$111.70M-82.6%
Q3 FY2023Sep 30, 2023$87.80M-63.6%
Q2 FY2023Jun 30, 2023$88.60M-75.3%
Q1 FY2023Mar 31, 2023$430.20M-1.3%
Q4 FY2022Dec 31, 2022$642.60M+11.5%
Q3 FY2022Sep 30, 2022$240.90M-40.4%
Q2 FY2022Jun 30, 2022$358.30M-20.0%
Q1 FY2022Mar 31, 2022$436.00M-20.4%
Q4 FY2021Dec 31, 2021$576.30M-7.3%
Q3 FY2021Sep 30, 2021$404.00M-2.7%
Q2 FY2021Jun 30, 2021$447.70M+66.4%
Q1 FY2021Mar 31, 2021$548.00M+201.6%
Q4 FY2020Dec 31, 2020$621.50M+269.9%
Q3 FY2020Sep 30, 2020$415.20M+197.8%
Q2 FY2020Jun 30, 2020$269.00M+51.5%
Q1 FY2020Mar 31, 2020$181.70M+32.2%
Q4 FY2019Dec 31, 2019$168.00M+49.5%
Q3 FY2019Sep 30, 2019$139.40M-59.0%
Q2 FY2019Jun 30, 2019$177.60M-7.2%
Q1 FY2019Mar 31, 2019$137.40M-16.5%
Q4 FY2018Dec 31, 2018$112.40M-37.3%
Q3 FY2018Sep 30, 2018$340.40M-0.2%
Q2 FY2018Jun 30, 2018$191.30M-39.4%
Q1 FY2018Mar 31, 2018$164.60M-39.1%
Q4 FY2017Dec 31, 2017$179.30M-34.2%
Q3 FY2017Sep 30, 2017$340.99M–
Q2 FY2017Jun 30, 2017$315.63M–
Q1 FY2017Mar 31, 2017$270.17M–
Q4 FY2016Dec 31, 2016$272.50M–

More Emergent BioSolutions figures

See a number that looks wrong?